Quote | Caribou Biosciences Inc. (NASDAQ:CRBU)
Last: | $3.39 |
---|---|
Change Percent: | -0.28% |
Open: | $3.6 |
Close: | $3.39 |
High: | $3.6398 |
Low: | $3.365 |
Volume: | 2,506,813 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
News | Caribou Biosciences Inc. (NASDAQ:CRBU)
2024-05-16 16:30:03 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for CRBU on May 16, 2024 02:01PM ET. The previous analyst recommendation was Underperform. CRBU was trading at $3.585 at issue of the analyst recommendation. The overall analyst consensus :...
2024-05-07 17:46:38 ET More on Caribou Bioscience Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value Caribou Biosciences received IND clearance from FDA for its lupus treatment Caribou Bioscience GAAP EPS of -$0.39 in-line, revenue of $3.56M misse...
Message Board Posts | Caribou Biosciences Inc. (NASDAQ:CRBU)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Caribou Biosciences Inc. Company Name:
CRBU Stock Symbol:
NASDAQ Market:
At the RBC Global Healthcare Conference, held on 14-15 May, RBC’s Healthcare Desk Sector Strategist gauged biotech investor sentime...
2024-05-16 16:30:03 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for CRBU on May 16, 2024 02:01PM ET. The previous analyst recommendation was Underperform. CRBU was trading at $3.585 at issue of the analyst recommendation. The overall analyst consensus :...
-- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- -- Expanding into autoimmune diseases with IND cleared for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Pha...